BACKGROUND: Although pregnant women are at increased risk of severe illness following influenza infection, there is relatively little information on the immunogenicity of influenza vaccines administered during pregnancy. METHODS: We conducted a clinical trial that enrolled 120 pregnant women in which participants were randomly assigned to receive an inactivated 2009 H1N1 influenza vaccine containing either 25 μg or 49 μg of hemagglutinin (HA) in a 2-dose series with a 21-day period between administration of the first and second doses. RESULTS: Following the first vaccination, HA inhibition (HAI) titers of ≥1:40 were detected in 93% (95% confidence interval [CI], 82%-98%) of subjects who received the 25-μg dose and 97% (95% CI, 88%-100%) of subjects receiving the 49-μg dose. In cord blood samples, HAI titers of ≥1:40 were found in 87% (95% CI, 73%-96%) of samples from the 25-μg dose group and in 89% (95% CI, 76%-96%) from the 49-μg dose group. Microneutralization titers tended to be higher than HAI titers, but the patterns of response were similar. CONCLUSIONS: In pregnant women, 1 dose of an inactivated 2009 H1N1 influenza vaccine containing 25 μg of HA elicited an antibody response typically associated with protection against influenza infection. Efficient transplacental transfer of antibody was also documented.
RCT Entities:
BACKGROUND: Although pregnant women are at increased risk of severe illness following influenza infection, there is relatively little information on the immunogenicity of influenza vaccines administered during pregnancy. METHODS: We conducted a clinical trial that enrolled 120 pregnant women in which participants were randomly assigned to receive an inactivated 2009 H1N1 influenza vaccine containing either 25 μg or 49 μg of hemagglutinin (HA) in a 2-dose series with a 21-day period between administration of the first and second doses. RESULTS: Following the first vaccination, HA inhibition (HAI) titers of ≥1:40 were detected in 93% (95% confidence interval [CI], 82%-98%) of subjects who received the 25-μg dose and 97% (95% CI, 88%-100%) of subjects receiving the 49-μg dose. In cord blood samples, HAI titers of ≥1:40 were found in 87% (95% CI, 73%-96%) of samples from the 25-μg dose group and in 89% (95% CI, 76%-96%) from the 49-μg dose group. Microneutralization titers tended to be higher than HAI titers, but the patterns of response were similar. CONCLUSIONS: In pregnant women, 1 dose of an inactivated 2009 H1N1 influenza vaccine containing 25 μg of HA elicited an antibody response typically associated with protection against influenza infection. Efficient transplacental transfer of antibody was also documented.
Authors: C F N Koegelenberg; E M Irusen; R Cooper; A H Diacon; J J Taljaard; A Mowlana; F von Groote-Bidlingmaier; C T Bolliger Journal: QJM Date: 2010-03-10
Authors: L A Jackson; G Austin; R T Chen; R Stout; F DeStefano; G J Gorse; F K Newman; O Yu; B G Weniger Journal: Vaccine Date: 2001-09-14 Impact factor: 3.641
Authors: Andrew C Miller; Farnaz Safi; Sadia Hussain; Ramanand A Subramanian; Elamin M Elamin; Richard Sinert Journal: Arch Intern Med Date: 2010-05-24
Authors: Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill Journal: Vaccine Date: 2009-03-25 Impact factor: 3.641
Authors: Denise J Jamieson; Margaret A Honein; Sonja A Rasmussen; Jennifer L Williams; David L Swerdlow; Matthew S Biggerstaff; Stephen Lindstrom; Janice K Louie; Cara M Christ; Susan R Bohm; Vincent P Fonseca; Kathleen A Ritger; Daniel J Kuhles; Paula Eggers; Hollianne Bruce; Heidi A Davidson; Emily Lutterloh; Meghan L Harris; Colleen Burke; Noelle Cocoros; Lyn Finelli; Kitty F MacFarlane; Bo Shu; Sonja J Olsen Journal: Lancet Date: 2009-07-28 Impact factor: 79.321
Authors: Seema Jain; Laurie Kamimoto; Anna M Bramley; Ann M Schmitz; Stephen R Benoit; Janice Louie; David E Sugerman; Jean K Druckenmiller; Kathleen A Ritger; Rashmi Chugh; Supriya Jasuja; Meredith Deutscher; Sanny Chen; John D Walker; Jeffrey S Duchin; Susan Lett; Susan Soliva; Eden V Wells; David Swerdlow; Timothy M Uyeki; Anthony E Fiore; Sonja J Olsen; Alicia M Fry; Carolyn B Bridges; Lyn Finelli Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245
Authors: Alexander W Kay; Nicholas L Bayless; Julia Fukuyama; Natali Aziz; Cornelia L Dekker; Sally Mackey; Gary E Swan; Mark M Davis; Catherine A Blish Journal: J Infect Dis Date: 2015-03-04 Impact factor: 5.226
Authors: Z Zhong; M Haltalli; B Holder; T Rice; B Donaldson; M O'Driscoll; K Le-Doare; B Kampmann; J S Tregoning Journal: Clin Exp Immunol Date: 2018-12-02 Impact factor: 4.330
Authors: Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel Journal: Vaccine Date: 2015-12-04 Impact factor: 3.641